PSNL Receives Medicare Reimbursement for Expanded Breast Cancer Indication, Adding Pre-Surgical Treatment Monitoring

Research evidence excerpt

PSNL Receives Medicare Reimbursement for Expanded Breast Cancer Indication, Adding Pre-Surgical Treatment Monitoring

FLASH NOTE

May 20, 2026

Subbu Nambi, Ph.D. subbu.nambi@guggenheimpartners.com PSNL Receives Medicare Reimbursement for

617 874 7383 Expanded Breast Cancer Indication, Adding Pre-

Thomas VonDerVellen

thomas.vondervellen@guggenheimpartners.com Surgical Treatment Monitoring

617 859 4657

Ricki Levitus Key Message: This morning, PSNL announced MolDx expanded reimbursement for

ricki.levitus@guggenheimpartners.com NeXT Personal in breast cancer to include pre-surgical neoadjuvant treatment monitoring 212 823 6556

for patients with stage II-III HR+/HER2- and TNBC. This reimbursement expansion is not

currently factored into PSNL's FY26 guidance, so this decision represents some upside,

though PSNL has not broken out the portion of volumes in this particular setting.

PSNL Recall, last November, PSNL received reimbursement for NeXT • Coverage Details:

Personalis, Inc. Personal in stage II-III HR+/HER2- and TNBC in the surveillance setting. Today's decision

Sector: Diagnostics & Life Sciences Tools expands the breast cancer treatment settings covered to include neoadjuvant treatment

monitoring, for the same patient population of stage II-III HR+/HER2- and TNBC. PSNL Company Update did not disclose the Medicare rate, but has previously said they expect pricing to be

Share Price $7.04 roughly similar across indications. Breast surveillance is reimbursed at $4,266 for the

NeXT Personal Dx MRD Recurrence Monitoring Test and $1,164 for the NeXT Personal

Single Plasma Test, likely the same rate applies to the neoadjuvant setting. Market Data

Indication Update: Guidance does not currently include reimbursement for IO 52-Week Range $3.84 - $11.50 •